Buccolam: prescribe by brand name to reduce medication errors

New guidance on the prescribing of buccal midazolam products has been issued by the Welsh medicines assessment body.

Buccolam is available in colour-coded pre-filled oral syringes, with age-specific doses, to reduce the risk of medication error
Buccolam is available in colour-coded pre-filled oral syringes, with age-specific doses, to reduce the risk of medication error

The All Wales Medicines Strategy Group (AWMSG) has highlighted the importance of prescribing Buccolam (buccal midazolam) by brand name to reduce the risk of medication errors.

Buccal midazolam is approved for the treatment of prolonged, acute, convulsive seizures in children aged between 3 months and 18 years. It has anticonvulsant, sedative and muscle-relaxant effects.

Treatment of infants 3–6 months of age should take place in the hospital setting, where monitoring and resuscitation equipment is available.

View Buccolam drug record

Further information: ViroPharma Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more